The estimated Net Worth of Elly Ryu is at least $108 millier dollars as of 2 March 2023. Ms Ryu owns over 17,289 units of Sesen Bio stock worth over $93,633 and over the last 3 years she sold SESN stock worth over $14,424.
Ms has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 17,289 units of SESN stock worth $10,201 on 2 March 2023.
The largest trade she's ever made was selling 17,289 units of Sesen Bio stock on 2 March 2023 worth over $10,201. On average, Ms trades about 4,890 units every 2 days since 2021. As of 2 March 2023 she still owns at least 148,624 units of Sesen Bio stock.
You can see the complete history of Ms Ryu stock trades at the bottom of the page.
Elly Ryu is the Corp. Controller & Principal Accounting Officer at Sesen Bio.
Ms Ryu is 40, she's been the Corp. Controller & Principal Accounting Officer of Sesen Bio since . There are 16 older and no younger executives at Sesen Bio. The oldest executive at Sesen Bio Inc. is Dr. Glen C. MacDonald, 70, who is the Chief Technology Officer.
Elly's mailing address filed with the SEC is C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes et Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Sesen Bio executives and other stock owners filed with the SEC include: